Continuous Blood Glucose Monitoring Market Synopsis

Continuous Blood Glucose Monitoring Market Size Was Valued at USD 11.63 Billion in 2024 and is Projected to Reach USD 54.69 Billion by 2032, Growing at a CAGR of 21.35 % From 2025-2032.

Continuous glucose monitoring means using a device to automatically estimate your blood glucose level, also called blood sugar, throughout the day and night. The continuous blood glucose monitoring (CGM) market was experiencing rapid growth, driven by increasing diabetes prevalence, advancements in CGM technology, and a growing awareness of the benefits of continuous glucose monitoring.

CGM devices are minimally invasive and offer an easy and effective way to manage diabetes. They can also detect drastic changes in blood glucose levels, thereby preventing hypoglycemic conditions. The CGM devices facilitate the analysis of blood glucose levels at different time intervals with the help of a sensor. Respective readings fed into diabetes management software through a wireless network allow patients to understand the disease better, thereby helping them to manage it more effectively.

In addition to high blood pressure and high cholesterol, common risk factors for diabetes complications include smoking, obesity, inactivity, and being overweight. According to the International Diabetes Federation, there will be 536.6 million people with diabetes worldwide in 2021.

Through the use of CGM devices, patients can receive information on their food intake, medication use, physical activity, and illnesses. Connecting with diabetes patients has become simpler for CGM device manufacturers thanks to the development of digital therapeutics. Numerous apps on the market combine CGM data for future trend analysis and lifestyle adjustments that the patient needs to make. All of these elements are anticipated to have a positive impact on the expansion of the market for continuous glucose monitoring devices.

The Continuous Blood Glucose Monitoring Market Trend Analysis - Rising Prevalence of Diabetes to Surge the Demand for Blood Glucose Monitoring

• The rising prevalence of diabetes is primarily caused by several factors, including rapid urbanization and the rising trend toward a sedentary lifestyle in emerging and developed nations. For instance, the International Diabetes Federation reported that in 2021, there were an estimated 537 million adults worldwide who had diabetes, with China, India, the United States, Brazil, and Mexico making up an estimated 51.6% of those individuals. The number of people with type 1 or insulin-dependent type 2 diabetes has significantly increased, which has accelerated the adoption of these systems internationally.
• For instance, according to the data published by the International Diabetes Federation, in 2021, it was estimated that the incidence of type 1 diabetes was 149.5 per 1,000 in children and adolescents aged (0-19) years and the global prevalence was around 9.8% among the total population. Thus, the presence of a large diabetic population suffering from insulin-dependent diabetes, new product introduction by market players, and favorable reimbursement are fueling the demand and adoption of diabetes monitoring products such as BGMs.

Increased Diabetes Prevalence

• The escalating global prevalence of diabetes provides a significant and enduring opportunity for Continuous Blood Glucose Monitoring (CGM) manufacturers. This trend is primarily propelled by a convergence of factors, including aging populations, sedentary lifestyles, and unhealthy dietary habits. As the world's population ages, the incidence of diabetes rises since the elderly are more susceptible to this condition. This demographic shift creates a sustained demand for effective glucose-monitoring solutions.
• The prevalence of sedentary lifestyles and poor dietary choices has led to an upsurge in type 2 diabetes cases, even among younger age groups. CGM can play a pivotal role in managing this form of diabetes, offering manufacturers an opportunity to cater to a broader spectrum of patients.
• Furthermore, the increasing recognition of the benefits of proactive diabetes management underscores the importance of CGM. Tight glucose control is crucial in preventing complications, and CGM systems empower individuals to make informed decisions about their diabetes management in real-time.

Continuous Blood Glucose Monitoring Market Segment Analysis

Continuous Blood Glucose Monitoring market segments cover the Product, application, and end-users. By Product, the Sensors segment is anticipated to dominate the Market over the Forecast period.

• Sensors are the most sophisticated part of CGM devices and consist of a metallic filament, thinner than a needle, which is inserted into the fatty layer just below the skin. The technology used in sensors is slightly different than the one used in transmitters and receivers. These components use glucose oxidase to detect blood sugar levels.
• Continuous glucose monitoring (CGM) sensors are portable devices that allow measuring and visualizing the glucose concentration almost continuously (usually every 1–5 min) for several days (so far up to seven days). CGM sensors are composed of three main elements: (i) a needle-based sensor, which is usually inserted in the abdominal subcutis and measures an electrical signal proportional to the glucose concentration present in the interstitial fluid; (ii) a transmitter, which is applied over the sensor and is aimed at transmitting the signal; and (iii) a portable device, which receives the signal and visualizes it on a monitor.
• In particular, the final signal is a glucose concentration, and it is obtained by converting the raw electrical signal measured by the sensor via a calibration procedure that exploits one or more reference blood glucose (BG) values collected using a portable self-monitoring BG (SMBG) device. Note that the calibration can take place either in the transmitter or in the receiver.

Continuous Blood Glucose Monitoring Market Regional Analysis

North America is expected to dominate the Market over the Forecast period.

• The countries in the North American region depict a high prevalence of diabetes. Due to the large pool of patients and wider acceptance of advanced technologies, the United States held the largest share of the glucose monitoring market in 2019. According to the International Diabetes Federation (IDF), approximations, in 2019, 463 million adults (aged 20-79) around the world had diabetes, including 31 million in the United States.
• Besides, other factors, such as new advancements and innovations, give many conveniences in measuring blood glucose levels. The innovations from start-up companies in the U.S., having around 2.9 billion in funding in the diabetes industry like Glooko, OneDrop, verily, Vacate, Insulet, Noom, Bigfoot Biomedical, Virta Health, Diabeloop, Orgenesis, etc., drive the United States market.
• The emergence of CGM has revolutionized the blood sugar monitoring process, as CGM-based devices monitor blood sugar every few minutes through a tiny sensor inserted under the patient's skin and relay results wirelessly to a pump, tablet, or other units.

Top Key Players Covered in The Continuous Blood Glucose Monitoring Market

• Abbott (U.S.)
• ACON Laboratories (US)
• ARKRAY (Japan)
• Ascensia Diabetes Care Holdings AG (Switzerland)
• B. Braun Melsungen AG (Germany)
• Beta Bionics, Inc. (US)
• Dexcom, Inc. (U.S.)
• Echo Therapeutics Inc. (US)
• F. Hoffmann-La Roche Ltd (Switzerland)
• GlySens Incorporated (US)
• Integrity Applications Inc.
• LifeScan IP Holdings, LLC (U.S.)
• Medisana AG (Germany)
• Medtronic (Ireland)
• Metronom Health Inc. (US)
• Nipro (Japan)
• Nova Biomedical (US)
• OrSense Ltd. (Israel)
• PKvitality (France)
• Prodigy Diabetes Care (US)
• Sanofi (France)
• Senseonics (U.S.)
• Siren Care, Inc. (US)
• Terumo Corporation (Japan)
• Ypsomed (Switzerland), and Other Active players.

Key Industry Developments in the Continuous Blood Glucose Monitoring Market

• In September 2023, Nemaura Medical Inc. announced its strategic partnership with Eversana for the introduction of Nemaura's cutting-edge diabetes management system in the United States. This collaboration promises to revolutionize diabetes care, providing innovative solutions to patients nationwide. Together, we are committed to improving the lives of those living with diabetes.
• In March 2023, Abbott is thrilled to announce the U.S. FDA has approved our FreeStyle Libre 2 and FreeStyle Libre 3 integrated Continuous Glucose Monitoring (CGM) sensors to be seamlessly integrated with automated insulin delivery systems. This milestone marks a significant advancement in diabetes care, empowering patients with enhanced control and convenience. Abbott remains committed to innovation in diabetes management.